Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Sunday that it has agreed an additional AI-empowered drug discovery collaboration with China Medical System Holdings Limited (CMS) (HKEX:867) (SGX:8A8) targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.
The two parties aim to jointly advance the co-development of the R&D programme by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise.
Insilico Medicine is eligible to receive up to approximately CNY1.2bn in milestone payments plus royalties.
The collaboration leverages both parties' complementary strengths across the full value chain, from drug discovery and clinical development to commercialisation.
Roche expands cyclospora testing portfolio to support US public health response
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab
Citius Oncology reports growing LYMPHIR adoption and market access
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation